Radiotherapy for Liver Metastases: A Review of Evidence

Høyer, Morten; Swaminath, Anand; Bydder, Sean; Lock, Michael; Romero, Alejandra Méndez; Kavanagh, Brian D.; Goodman, Karyn A.; Okunieff, Paul; Dawson, Laura A.

doi:10.1016/j.ijrobp.2011.07.020

Cited by 170 publications

(115 citation statements)

References 74 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Despite important advances, such as sorafenib and Y90, overall outcomes in patients with liver cancer remain dismal [2]. There is growing evidence that external beam radiation provides favorable local control and drives improvement in primary clinical outcomes [3,4]. In addition, the availability of highly conformal delivery techniques and the resulting improvement in treatment safety and tolerability have led to increasing use of radiation for liver cancer [5,6].…”

Section: Introductionmentioning

confidence: 99%

Computed Tomography Imaging Assessment of Postexternal Beam Radiation Changes of the Liver

et al. 2016

Self Cite

View full text Add to dashboard Cite

Radiation is being used for patients with primary and secondary liver cancers, as a rapidly evolving treatment. However, postradiation imaging changes of the liver are not well understood and therefore challenging to interpret. Distinguishing normal radiation changes from residual or recurrent disease is difficult. Size and contrast enhancement have been used to guide interpretation and clinical recommendations, but normal radiation changes can make interpretation difficult and are not accounted for in available guidelines. Knowledge of dose- and time-dependent changes in addition to imaging findings, such as morphological and enhancement patterns, provides useful differentiating parameters. This paper reviews recent studies using computed tomography that can guide interpretation and help differentiate tumor from benign changes after external beam radiation.

show abstract

Section: Introductionmentioning

confidence: 99%

Computed Tomography Imaging Assessment of Postexternal Beam Radiation Changes of the Liver

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The dose required for a favorable result of the radiotherapy treatment might be 24-30 Gy in a single dose, 45-60 Gy in 3 fractions, 40-50 Gy in 5 fractions, 48-60 Gy in 6 fractions. 1,10,18,23,24 …”

Section: Dosementioning

confidence: 99%

“…One grade 3 toxicity among 15 diarrheas was reported in this study. 23 For pancreatic tumor stereotaxy, Murphy et al 33 have proposed a dosimetric model of duodenal toxicity. The duodenal delineation was specified with precision for 73 patients irradiated with a single 25 Gy dose 14 days after the last Gemcitabine treatment administration.…”

Section: Stomach Duodenal and Bowel Toxicitiesmentioning

confidence: 99%

Dose to organ at risk and dose prescription in liver SBRT

Rives

Izar

Parent

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.

show abstract

“…Several studies on liver SBRT confirmed the correlation between dose prescription and local control. [18][19][20][21][22] For SBRT in 3 fractions, a prescription dose ranging from 48 to 60 Gy should be considered for lesions with a diameter ≤3 cm. 22,23 A total dose of 60 Gy or higher should be recommended for lesions with a diameter >3 cm.…”

Section: Stereotactic Body Radiation Therapy (Sbrt) For Liver Metastamentioning

confidence: 99%

The role of SBRT in oligometastatic patients with liver metastases from breast cancer

Scorsetti

Franceschini

Rose

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Liver Metastases SBRT Radiotherapy a b s t r a c tLiver metastases from breast cancer are a common occurrence. Local ablative therapies are a promising therapeutic option for these patients, with the potential for a long term disease control in the setting of "oligometastatic patients". Identification of the perfect candidate for local approaches is still challenging and unclear. Stereotactic body radiation therapy (SBRT) is one of the most valuable local therapy, because of great efficiency, low morbidity and minimal invasiveness. In this paper, we reviewed the state of the art in the care of breast cancer patients with liver metastases, with a focus on SBRT.© 2016 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved. 1.State of the art E-mail address: marta.scorsetti@humanitas.it (M. Scorsetti).Firstly in 1995, Hellman and Weichselbaum 1 described the state, called oligometastatic disease, characterized by an indolent tumor biology and behavior in which metastases are limited in number and site. In this subgroup of selected patients, the emerging data is that local therapy could have a potential curative role and an impact on survival rate.The population with oligometastatic BC (OM BC) is estimated to be 1-10% of newly diagnosed patients with metastatic BC 2 and is well represented in the subgroup of http://dx

show abstract

Radiotherapy for Liver Metastases: A Review of Evidence

Cited by 170 publications

References 74 publications

Computed Tomography Imaging Assessment of Postexternal Beam Radiation Changes of the Liver

Computed Tomography Imaging Assessment of Postexternal Beam Radiation Changes of the Liver

Dose to organ at risk and dose prescription in liver SBRT

The role of SBRT in oligometastatic patients with liver metastases from breast cancer

Contact Info

Product

Resources

About